恩替卡韦分散片早期抗病毒治疗对乙型肝炎相关慢加急性肝功能衰竭患者的疗效及短期预后的影响观察  

Effect of Early Antiviral Treatment of Entecavir Dispersible Tablets on the Efficacy and Short-term Prognosis of Patients with Hepatitis B-related Chronic and Acute Liver Failure

作　　者：邓洪菊 DENG Hong-ju(The Second Infectious Ward,the Sixth People's Hospital of Benxi,Benxi 117000,China)

机构地区：[1]辽宁省本溪市第六人民医院感染二病房,辽宁本溪117000

出　　处：《中国医药指南》2020年第11期82-83,共2页Guide of China Medicine

摘　　要：目的观察恩替卡韦分散片早期抗病毒治疗对乙型肝炎相关慢加急性肝功能衰竭患者的疗效及短期预后的影响。方法选择我院于2016年11月至2018年11月收治的116(减半)例乙型肝炎相关慢加急性肝功能衰竭(HBV-ACLF)患者作为研究对象,按照不同的治疗方法分为对照组和观察组,各58例。两组患者均进行内科综合治疗,观察组患者采用恩替卡韦分散片(ETV)进行治疗,对照组患者采用拉米夫定片(LAM)进行治疗。比较两组患者治疗1、2周时的生化指标,比较两组治疗2周时的生存率,比较两组治疗4周时的HBV DNA载量,比较两组患者治疗12周时的治疗总有效率。结果治疗1、2周时,各个时间段两组患者的生活指标检验结果差异不显著,无统计学意义(P>0.05)。治疗2周时,观察组患者的生存率明显高于对照组患者,差异显著,有统计学意义(P<0.05)。治疗4周时,两组患者的HBV DNA载量检验结果差异不显著,无统计学意义(P>0.05)。治疗12周时,两组患者的治疗有效率检验结果差异不显著,无统计学意义(P>0.05)。结论对于HBV-ACLF患者而言,采用ETV早期抗病毒治疗能够取得比较好的疗效,起效快,能提升患者的早期生存率。Objective To observe the effect of early antiviral therapy with entecavir on the short-term prognosis of patients with chronic and acute hepatitis B-related liver failure.Methods 116 patients with hepatitis B-related chronic and acute liver failure(HBV-ACLF)admitted to our hospital from November 2016 to November 2018 were selected as the research objects.According to different treatment methods,they were divided into control group and observation group,58 cases in each group.Both groups were treated with comprehensive medical treatment.The patients in the observation group were treated with entecavir(ETV),while the patients in the control group were treated with lamivudine(LAM).The biochemical indicators and survival rates of the two groups at 1,2,4 and 12 weeks of treatment were compared.The HBV DNA load at 4 weeks of treatment was compared between the two groups,and the total effective rate at 12 weeks of treatment was compared between the two groups.Results At 1,2,4 and 12 weeks of treatment,there was no signifi cant difference in the results of life index test between the two groups at each time period(P>0.05).At 4 weeks of treatment,there was no signifi cant difference in HBV DNA load between the two groups(P>0.05).At 12 weeks of treatment,there was no signifi cant difference between the two groups(P>0.05).Conclusion For patients with HBV-ACLF,ETV early antiviral therapy can achieve better curative effect,quick onset,and improve the early survival rate of patients.

关 键 词：恩替卡韦分散片 乙型肝炎 短期预后 急性肝功能衰竭 拉米夫定片 

分 类 号：R512.62[医药卫生—内科学] R575.3[医药卫生—临床医学]